Developed in collaboration with the University of Oxford and Novavax’s Matrix-M adjuvant, the R21/Matrix-M vaccine is the second malaria vaccine to be authorised for use in children in malaria-endemic regions, SII said India Developed in collaboration with the University of Oxford and Novavax’s Matrix-M adjuvant, the R21/Matrix-M vaccine is the second malaria vaccine to be authorised for use in children in malaria-endemic regions, SII said Sci-Tech News | Latest Technological Developments | The Hindu
SII commences shipments of malaria vaccine ‘R21/Matrix-M’ to Africa
